Amporin Pharmaceuticals develops small molecule membrane-protecting therapies for neurodegenerative diseases linked to protein misfolding. The company focuses on creating orally available, brain-penetrating drugs that specifically target and block or inhibit toxic amyloid pores in cellular membranes. This approach aims to prevent cell death and degeneration caused by uncontrolled ion influx in conditions like ALS and Alzheimer's.
Funding
$170.3K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many complex diseases lack effective therapies, resulting in poor patient outcomes and high healthcare costs. Current treatment options may not be targeted or may have limited efficacy.
Solution
Amporin Pharmaceuticals is developing a novel class of small-molecule medications designed to address complex diseases with unmet medical needs. The company employs advanced drug discovery techniques to create targeted treatments. These treatments aim to improve patient outcomes by directly addressing the underlying mechanisms of disease. The focus is on developing therapies that are both effective and can potentially reduce overall healthcare expenditures.
Target Audience
The primary target audience includes patients suffering from complex diseases lacking effective therapies, as well as healthcare providers seeking improved treatment options.
Features
- Development of small-molecule medications
- Utilization of advanced drug discovery techniques
- Focus on targeted treatments for complex diseases